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Abstract:  Neurotoxin  receptor  site  1, in  the outer  vestibule  of the conducting  pore of 
voltage-gated sodium channels (VGSCs), was first functionally defined by its ability to 
bind  the  guanidinium-containing  agents,  tetrodotoxin  (TTX)  and  saxitoxin  (STX). 
Subsequent studies showed that peptide μ-conotoxins competed for binding at site 1. All of 
these natural inhibitors block single sodium channels in an all-or-none manner on binding. 
With the discovery of an increasing variety of μ-conotoxins, and the synthesis of numerous 
derivatives, observed interactions between the channel and these different ligands have 
become  more  complex.  Certain  μ-conotoxin  derivatives  block  single-channel  currents 
partially, rather than completely, thus enabling the demonstration of interactions between 
the  bound  toxin  and  the  channel’s  voltage  sensor.  Most  recently,  the  relatively  small  
μ-conotoxin  KIIIA  (16  amino  acids)  and  its  variants  have  been  shown  to  bind 
simultaneously with TTX and exhibit both synergistic and antagonistic interactions with 
TTX. These interactions raise new pharmacological possibilities and place new constraints 
on the possible structures of the bound complexes of VGSCs with these toxins. 
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1. Introduction 
Tetrodotoxin (TTX) was the first pharmacological agent targeted to voltage-gated sodium channels 
(VGSCs) that was characterized (see Narahashi [1] for a personal historical account). A variety of 
pharmacologically  active  compounds,  which  affected  VGSC  function,  were  subsequently 
characterized.  In  order  to  provide  a  rational  framework  for  the  analysis  of  these  very  different 
compounds, Catterall and co-workers [2–4] classified the known sodium channel ligands according to 
their  sites  of  action.  This  has  remained  an  important  differentiating  scheme  in  sodium  channel 
pharmacology. Thus, every compound believed to act at the same pharmacological site as tetrodotoxin 
is  referred  to  as  a  ligand  of  neurotoxin  receptor  site  1.  Saxitoxin  (STX)  and  its  derivatives  are 
associated  with  paralytic  shellfish  poisoning,  which  occurs  during  harmful  algal  blooms,  and  are 
among the most important site 1 ligands that were identified after the discovery of TTX [5]. 
From animal venoms, one family of peptides has been identified that consists of site 1 ligands: the 
μ-conotoxins expressed in the venom ducts of fish-hunting cone snails. It is noteworthy that other 
venom  components,  which  target  different  physiological  sites  on  the  Na  channel,  are  much  more 
widely distributed among different venoms, but, to date, site 1 compounds have only been reported 
from cone snail venoms. These peptides are generally regarded as part of the prey-capture cocktail that 
the snails have evolved, and are considered to be part of the “motor cabal” group of peptide toxins, 
which act in a coordinated and synergistic fashion to completely inhibit neuromuscular transmission in 
the envenomated prey [6]. The archetypal μCTX GIIIA was shown to induce all-or-none block of 
single, skeletal-muscle VGSCs, and to compete for site 1 in binding assays [7,8]. Later, it was found 
that even the incompletely blocking derivative GIIIA[R13Q] competed for exclusive occupancy of  
site 1 (see Figure 1). 
In passing, we note that, in addition to -conotoxins, at least three additional families of peptides 
from cone snails have been identified that target VGSCs. Members of all three families are gating 
modifiers:  O-conotoxins,  which  block  channel  activation;  -conotoxins,  which  block  channel 
inactivation;  and  -conotoxins  (or  iota-conotoxins),  which  promote  channel  activation  [6,9].  Thus,  
- and O-conotoxins are channel antagonists, whereas - and -conotoxins are channel agonists.  
As the only currently known peptide ligands for site 1, the μ-conotoxins have been exploited to 
identify which amino acids on the Na channel are located around site 1 [10]. Variation in site 1 among 
Na channel subtypes from different species can, in principle, be investigated through the interactions 
between the different Na channels and μ-conotoxins or derivatives of μ-conopeptides [7,8,11]. Thus, 
μ-conopeptides  are  attractive  probes  for  the  exploration  of  the  topology  and  three-dimensional 
structure of this pharmacologically important site [12–14]. In addition, the net positive charge on the 
peptides  allows  them  to  participate  in  numerous  long-range  electrostatic  interactions,  which  can 
contribute to binding [15] and to the blocking of ion conduction [16,17]. Electrostatic interactions also 
modulate gating [18] and drug binding at locations other than site 1, e.g., the amine binding site that 
makes up part of the local anaesthetic receptor, site 9 [18,19]. This latter interaction may be mediated, 
at least in part, via interactions with permeant ions [20]. 
Of  particular  interest  is  recent  work  investigating  the  interaction  between  μ-conopeptides  and 
TTX/STX, which reveals that “site 1”, as conventionally defined by pharmacological criteria, is likely 
a more complex biochemical entity than previously envisioned. TTX is thought to occupy a site within Mar. Drugs 2010, 8  
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the vestibule of the ion channel near the extracellular end of the channel pore, and, by binding to this 
site, to occlude the permeation pathway of sodium ions through the pore. The prevailing view is that  
μ-conopeptides, being larger than tetrodotoxin, occupy a site that spatially overlaps the TTX binding 
site, but that amino acid residues in the ion channel vestibule further out from the mouth of the pore 
can contribute to binding of the peptide ligand, even though they do not interact with TTX. In this 
view, site 1 has two sub-sites: a core that can be occupied by a guanidinium toxin or a μ-conopeptide, 
and a more peripheral zone that interacts with the peptide, but not TTX or STX.  
Figure 1. Steady-state recordings from a single, rat skeletal muscle sodium channel enable 
discrete recognition and analysis of blocking events induced by derivatives of both STX 
and  the  conotoxin,  μCTX  GIIIA.  The  channel  has  been  modified  by  batrachotoxin  to 
prevent inactivation. Voltage-dependent activation gating and block by site 1 ligands are 
retained. (a) Typical all-or-none block, resulting from guanidinium toxins, such as TTX 
and STX, exemplified by the saxitoxin derivative, decarbamoyl-STX (dcSTX); (b) After 
addition  of  peptide  μCTX  GIIIA[R13Q],  prominent  partial  blocking  events  are  seen, 
reducing current by ~70%. The fully blocked/closed level is indicated by the solid line; the 
partially  blocked  level  produced  by  R13Q  is  indicated  by  the  dotted  line;  (c)  After 
increasing the concentrations of both dcSTX and R13Q, the channel is bound most of the 
time, but in a manner consistent with simple, competitive binding, each fully blocked state 
(dcSTX-bound),  and  each  partially  blocked  state  (R13Q-bound),  is  preceded  by  an 
unblocked  state,  which  is  relatively  brief  at  these  high  concentrations  of  the  toxins. 
Adapted from French et al., Neuron, 1996 [18]. 
 
2. Newly Discovered Complexities of Interactions between TTX and μ-Conopeptides 
In  the sections  that  follow, we discuss  recent work that  reveals  that the notion of competitive 
occupancy of the site 1 core, by either a μ-conopeptide or tetrodotoxin molecule, needs to be revisited. 
In some cases, both ligands can simultaneously bind to a given channel, contradicting the expectation 
that  site  1  ligands  are  mutually  exclusive  in  binding  to  site  1.  Furthermore,  some  experimental 
evidence  indicates  that  even  though  a  μ-conopeptide  is  bound  at  site  1  and  attenuates  channel 
conductance, it is apparently still possible for TTX to “sneak” past the conopeptide and bind to its site 
that is presumably deeper in the outer vestibule of the channel to totally occlude the pore. 
(a) 
(b) 
(c) Mar. Drugs 2010, 8  
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Recent investigation of potential interactions between TTX and μ-conopeptides has its origins in 
early observations with single-channel recordings [11,18]. Mutation of the critical arginine residue 
that, in μCTX GIIIA, is believed to interact directly with the pore, results in a residual Na current that 
persists when the channel is occupied by the peptide (e.g., GIIIA[R13Q]). The residual current allows 
the lifetime and function of the toxin-bound channel to be electrophysiologically monitored. Thus, it 
could be shown that bound toxin influenced the channel's voltage sensor, a reflection of the proximity 
of the latter to site 1 [18]. This influence is further illustrated by the direct effect of μCTX GIIIA on 
gating charge movement (Figure 2). A reversible, positive shift in the plot of gating charge, Q, vs. 
voltage, V, indicates an inhibition of the outward motion of the positive charges on the voltage sensor 
when the polycationic toxin (nominal net charge, +6) is bound at site 1. 
Figure 2. μCTX GIIIA, with its nominal net charge of +6, shifts voltage dependent gating 
charge  movement  to  the  right,  which  is  consistent  with  the  cationic  peptide  impeding 
outward movement of the positive charge on the channel’s voltage sensor [21]. This is 
consistent with shifts in activation of both single channels in lipid bilayers and whole-cell 
currents [18]. Recording from fused tsA-201 cells expressing rat skeletal muscle VGSCs 
(rNaV1.4) [22]. 
 
Of  possible  interest  in  this  regard  is  the  peptide  Tx1  from  the  South  American  armed  spider 
Phoneutria nigriventer, which has been reported to have a binding site that overlaps with that of  
-GIIIA, but not that of TTX [23]. The reported voltage dependence of sodium current block by Tx1 
could,  in  principle,  arise  either  from  a  direct  interaction  with  the  voltage  sensor,  or  from  
state-dependent binding, but more experiments will be needed to clarify the mechanism. 
The residual currents of GIIIA derivatives were not blocked by decarbamoyl STX [18] (also see 
Figure 1), which is consistent with the classical notion that binding of -conotoxin and guanidinium 
toxins to site 1 was mutually exclusive. Residual currents, reminiscent of those observed with GIIIA 
derivatives and NaV1.4, have recently been observed in single channel measurements of the blocking 
of brain VGSCs by the newly discovered -conotoxin KIIIA [24]. Those observations inspired us to 
see whether: (A) a corresponding residual current could be observed when macroscopic currents were 
studied, and if so, (B) if the macroscopic current were susceptible to block by TTX [25]. Indeed, for Mar. Drugs 2010, 8  
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NaV1.2 expressed in oocytes that are exposed to saturating concentrations of KIIIA, a residual current 
(rINa), with an amplitude of 5% of the control INa, was observed. With the mutant KIIIA[K7A], the rINa 
was 23% of the control. A key discovery was that the addition of TTX to Na channels, with already 
bound KIIIA or KIIIA[K7A], produced a complete block, and that the onset of total block was very 
slow. One possible interpretation was that the peptide dissociated from the channel and was replaced 
by  TTX,  thereupon  resulting  in  a  complete  block  of  channel  conductance.  However,  several 
observations established that the peptide did not necessarily dissociate from the channel, and that a 
ternary peptide TTX NaV complex was formed (Figure 3).  
Figure  3.  Reaction  scheme  showing  simultaneous  binding  of  TTX  and  μCTX  KIIIA. 
Reproduced by permission from Zhang et al. 2009, Channels [25]. 
 
Most notably, there was a dramatic change in the time course of recovery when both TTX and the 
μ-conopeptide under these conditions were washed out. The rate of recovery was slower than that of 
following exposure to TTX alone, and faster than that of following exposure to peptide alone. The 
most straightforward explanation for this result is that both ligands were simultaneously bound to the 
outer vestibule of the channel, but that TTX was “trapped” at its site by the binding of the peptide, and, 
as a consequence, TTX could not dissociate with its usual rapid kinetics. However, binding of TTX 
also affected μ-conopeptide dissociation, because the off-rate for the peptide under these conditions 
was significantly faster than that which was observed in the absence of TTX. Reciprocally, the rate of 
dissociation  of  the  peptide  limited  the  off-rates  for  TTX,  and  these  off-rates  (C→A  and  C→B, 
respectively, Figure 3) differed from those observed for either the peptide (A→R) or TTX (B→R) 
alone. Also, the results suggested that the extremely slow on-rate for TTX (A→C) was not limited by 
dissociation of the peptide, but rather, reflected the slow rate of access by TTX to its binding site, 
when the peptide was bound to the channel.  
The  rate  of  conversion  from  a  partially  blocked  to  a  totally  blocked  channel,  and  the  rate  of 
functional recovery, after complete block had occurred and both toxins were washed out, therefore 
provide a measurable set of parameters that could be monitored using different μ-conopeptides and 
analogs of μ-conopeptides. One could also compare the effect of replacing TTX by STX, or various 
analogs  of  guanidinium  toxins  [26].  The  net  result  is  a  coherent  picture  of  interactions  between 
guanidinium toxins and μ-conopeptides (and their analogs) at site 1.  Mar. Drugs 2010, 8  
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Both the on-rate of the guanidinium toxin in the presence of μ-conopeptide and the off-rate of the 
toxin in the presence of TTX or STX are dependent on which specific μ-conopeptide (or analog) and 
which guanidinium toxin is being examined. In some cases, the guanidinium toxin cannot “sneak” past 
a μ-conopeptide at all. The interaction is determined in part by the charge of the guanidinium toxin and 
the placement of these charges; these factors influence the effect occupancy that the guanidinium toxin 
site has on the rate of μ-conopeptide dissociation, and can be rationalized by a charge repulsion model.  
3. Potential Applications of Double Occupancy of Site 1 
The possibility that the guanidinium toxins and certain μ-conopeptides or analogs of μ-conopeptides 
can simultaneously occupy site 1 raises some interesting pharmacological opportunities. At this time, 
these are only conceptual constructs, and proof-of-principle for real-world application needs to be 
worked out. However, since some unusual prospects are raised, especially with regard to modulating 
the pharmacology of channel block, we present some of the possibilities. 
3.1. Syntoxins 
When co-occupancy by peptide and guanidinium toxin of site 1 occurs, the two partners that occupy 
the site necessarily interact with each other. Thus, a selective alteration of one of the partners can 
cause a change in the interaction with the other partner. Thus, a μ-conopeptide that can sit in site 1 
simultaneously with TTX is what we regard as a syntoxin of TTX. When the μ-conopeptide is bound, 
the  dissociation  rate  of  TTX  is  slowed;  thus,  one  can  imagine  having  a  series  of  μ-conopeptide 
syntoxins resulting in a range of off times for TTX, depending on which μ-conopeptide syntoxin is  
co-occupying site 1.  
3.2. Contratoxins 
In principle, as the co-occupancy of site 1 by TTX/STX and μ-conopeptides is better understood, it 
should be possible to design analogs of μ-conopeptides that inhibit TTX, STX, and their analogs from 
bypassing the peptide to cause complete inhibition of channel conductance. One might imagine a 
tightly  bound  μ-conopeptide  analog  that  prevented  any  guanidinium  toxins  from  reaching  their 
pharmacological site. -Conopeptides with such properties could be used as a contratoxin, or antidote, 
to a red-tide poisoning. Administration of a contratoxin that has a significant residual current could, in 
principle, partially reverse the more life-threatening effects of the binding of the guanidinium toxins to 
VGSCs. Thus, by designing a μ-conopeptide derivative with a large residual current and yet very high 
affinity for site 1, an antidote for red tide poisoning might be produced. 
4. Recent Results 
Since submission of the current manuscript, two papers, which provide additional insight into the 
complexity of interactions between the µ-conotoxins and derivatives of TTX and STX, have been 
published online [26,27]. Mar. Drugs 2010, 8  
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